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Abstract
Background: More than 200 studies related to nucleic acid amplification (NAA) tests to detect
Mycobacterium tuberculosis directly from clinical specimens have appeared in the world literature
since this technology was first introduced. NAA tests come as either commercial kits or as tests
designed by the reporting investigators themselves (in-house tests). In-house tests vary widely in
their accuracy, and factors that contribute to heterogeneity in test accuracy are not well
characterized. Here, we used meta-analytical methods, including meta-regression, to identify
factors related to study design and assay protocols that affect test accuracy in order to identify
those factors associated with high estimates of accuracy.
Results: By searching multiple databases and sources, we identified 2520 potentially relevant
citations, and analyzed 84 separate studies from 65 publications that dealt with in-house NAA tests
to detect M. tuberculosis in sputum samples. Sources of heterogeneity in test accuracy estimates
were determined by subgroup and meta-regression analyses. Among 84 studies analyzed, the
sensitivity and specificity estimates varied widely; sensitivity varied from 9.4% to 100%, and
specificity estimates ranged from 5.6% to 100%. In the meta-regression analysis, the use of IS6110
as a target, and the use of nested PCR methods appeared to be significantly associated with higher
diagnostic accuracy.
Conclusion:  Estimates of accuracy of in-house NAA tests for tuberculosis are highly
heterogeneous. The use of IS6110 as an amplification target, and the use of nested PCR methods
appeared to be associated with higher diagnostic accuracy. However, the substantial heterogeneity
in both sensitivity and specificity of the in-house NAA tests rendered clinically useful estimates of
test accuracy difficult. Future development of NAA-based tests to detect M. tuberculosis from
sputum specimens should take into consideration these findings in improving accuracy of in-house
NAA tests.
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Background
Accurate and early diagnosis of tuberculosis (TB) is a crit-
ical step in the management and control of TB. Because
conventional tests for TB have several limitations, nucleic
acid amplification (NAA) tests have emerged as promising
alternatives. The polymerase chain reaction (PCR) is the
best-known and most widely used NAA test. NAA tests are
categorized as commercial (kit-based) or in-house
("home-brew"). In-house tests are those assays where the
investigators design their own protocols. In-house tests
are commonly used in developing countries where com-
mercial kits may not be affordable. The accuracy of NAA
tests for TB has been extensively studied since the early
1990s. Since hundreds of studies have evaluated the accu-
racy of NAA tests, it is now possible to evaluate their over-
all performance using meta-analysis methods and
determine which study design or test-related characteris-
tics are associated with higher diagnostic accuracy.
Several systematic reviews and meta-analyses have been
published in the past few years on the accuracy of NAA
tests for pulmonary and extra-pulmonary TB [1,5].
Because these meta-analyses and reviews have synthesized
data from over 200 primary studies, and because their
results are highly consistent with each other, they provide
us with the best available evidence on the accuracy of NAA
tests. The following are the main findings of the meta-
analyses and reviews: most of the studies on NAA tests
reported very high estimates of specificity, for both pul-
monary and extra-pulmonary TB [1-5]. Sensitivity esti-
mates, in contrast, have been much lower and highly
variable (heterogeneous) [1-5]. Sensitivity estimates have
been lower in paucibacillary forms of TB (smear-negative
pulmonary and extra-pulmonary TB), and higher in
smear-positive pulmonary TB [2,3]. Another striking
result is the widespread lack of consistency in accuracy
estimates across studies – studies have reported highly
variable estimates of test accuracy [1-5]. For example, in
our previous meta-analysis on NAA tests for tuberculous
meningitis, sensitivity estimates varied between 0 – 100%
[3]. In general, almost all the meta-analyses have demon-
strated that the sensitivity and specificity of in-house PCR
assays have been more variable and inconsistent than
commercial tests [2,3,5].
Why do studies on in-house PCR assays produce such
highly variable estimates of sensitivity and specificity? Is
the variability due to differences in study design or to dif-
ferences in assay characteristics and laboratory tech-
niques? Are there specific study design features and assay
characteristics that yield higher estimates of accuracy?
Answers to these questions might help to identify features
of NAA tests that maximize accuracy. However, these
questions are difficult to address in individual studies.
Meta-analytic methods, on the other hand, are well suited
to explore the issue of why studies produce variable
results. By synthesizing data from multiple studies and
increasing the power of analyses, meta-analyses are able
to employ techniques that help to identify sources of het-
erogeneity in study findings. In this meta-analysis, we
reviewed 65 published studies on in-house NAA tests for
pulmonary TB. The main objective of our meta-analysis
was to determine factors associated with heterogeneity as
well as higher accuracy estimates of accuracy in studies
that evaluated in-house PCR for the diagnosis of pulmo-
nary TB.
Results
Study selection
By searching multiple databases and sources we identified
2520 potentially relevant citations on NAA tests for tuber-
culosis. After screening titles and abstracts, 434 English
and Spanish articles were selected for full-text review and
129 articles reported inclusion of sputum specimens
tested by an in-house PCR assay. Sixty-one articles were
then excluded mainly because data were not separately
provided for sputum samples (sputum and other clinical
specimens were analyzed together). Also, three articles
were excluded because real time PCR was used and the
number was insufficient to place them in a separate cate-
gory. A total of 65 articles [10-74], were included in the
final analysis. Four articles were in Spanish [19,41,46,53].
Thirteen articles reported evaluations of more than one
NAA test against a common reference standard
[11,13,14,20,28,36,47,54,60,62,68,69,72]. Each such test
comparison was counted as a separate study. Thus, the
total number of test comparisons (hereafter referred to as
studies) was 84.
Characteristics of included studies
The summary characteristics of the included studies are
shown in Table 1. The average sample size of the included
studies was 149 (range 14 to 727). Our data, as seen in
Table 1, were affected by the poor quality of reporting in
the primary studies. Fifty-five of 84 (65.5%) studies did
not report blinded interpretation of NAA test independent
of the reference standard, while only 29 of 84 (34.5%)
reported single or double blinding of NAA test and the ref-
erence standard. Most of the studies, 60 of 84 (72%), were
cross-sectional whereas 24 (28%) were case-control stud-
ies. The studies differed greatly in terms of laboratory
characteristics. Fifty-four of 84 (65%) studies used IS6110
as amplification target by itself or in combination with
other targets, and 30 studies (35%) used other targets (e.g.
MPB64, 38 kDa). The studies were categorized as those
using any chemical method for DNA extraction (includ-
ing phenol-chloroform) and those in which any physical
or mechanical extraction method was used. Sixty-eight of
84 (81%) studies reported a simple PCR protocol (includ-
ing multiplex PCR), whereas 16 (19%) studies used aBMC Microbiology 2005, 5:55 http://www.biomedcentral.com/1471-2180/5/55
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nested or seminested PCR protocol. Lastly, 49 of 84
(58%) studies used UV transillumination of an electro-
phoretic gel, and 35 (42%) used DNA hybridization
probes to detect the amplification products.
Overall diagnostic accuracy
When all 84 studies were evaluated together, the sensitiv-
ity estimates ranged from 9.4% to 100%, and specificity
estimates ranged from 5.6% to 100%. Both measures were
highly heterogeneous (P < 0.001 for test of heterogeneity).
Figure 1 shows the overall accuracy of PCR in a summary
receiver operating characteristic (SROC) plot. The sym-
metric curve shows a trade off between sensitivity and spe-
cificity. The area under the SROC curve was 97%, and
summary DOR was 159.4, indicating high accuracy. How-
ever, the significant heterogeneity in sensitivity and specif-
icity estimates precluded the determination of clinically
useful summary measures.
Exploration of heterogeneity
In order to identify factors associated with heterogeneity,
we performed stratified (subgroup) analyses. Table 2
presents the study quality and assay factors assessed and
their effect on the estimated summary Diagnostic Odds
Ratio (DOR). As seen in Table 2, studies that did not
report the use of blinding produced a DOR nearly 2.5
times higher than studies that reported blinded interpre-
tation of index test and reference standard results. Studies
with PCR tests that used a nested protocol had almost 2
times higher DOR than those using a regular PCR proto-
col. The use of IS6110 target in comparison with those
using any other target for amplification showed a DOR
1.7 times higher than studies that used other targets. A
similar result was obtained when studies that used UV
transillumination of a gel were compared to those that
used a probe for detection. Studies that used chemical rea-
gents for DNA extraction produced DOR estimates that
were about 1.12 times greater than studies that used phys-
ical methods, indicating that the use of chemicals (includ-
ing phenol chloroform) does not significantly improve
Table 1: Study characteristics and methodological quality of included studies
Study characteristic Frequency [N = 84 studies]
Study design
Cross sectional 60 (71%)
Case-control 24 (29%)
Blinded assessment of NAA test and reference standard results
Double or single blinded 29 (34%)
Unblinded or Unknown 55 (66%)
Target sequence for amplification
IS6110 54 (64%)
Other target sequences 30 (36%)
Use of chemical-based DNA extraction method
Any chemical method 55 (66%)
Physical methods 29 (34%)
Amplification technique
Nested or semi-nested PCR 16 (19%)
Regular or multi-plex PCR 68 (81%)
Detection of amplified products
Probe-based method 49 (58%)
Gel-UV method 35 (42%)
Summary Receiver Operative Curve (SROC) for all studies Figure 1
Summary Receiver Operative Curve (SROC) for all 
studies. Each solid circle represents each study in the meta-
analysis. The regression line summarizes the overall diagnos-
tic accuracy. Area under the curve (AUC) = 0.97.BMC Microbiology 2005, 5:55 http://www.biomedcentral.com/1471-2180/5/55
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the test accuracy. Only five studies reported the analysis
on smear negative samples. When stratified by smear sta-
tus, no major difference was seen in the DOR. But this
result may be due to the small number of studies report-
ing only smear negative samples for diagnosis.
As in our previous meta-analyses [2,3], none of the strati-
fied analyses for DOR results fully explained the signifi-
cant heterogeneity across studies in this review; the
statistical tests for heterogeneity were significant even
within the various strata (data not shown). Therefore, a
meta-regression analysis was performed (Table 3) to
simultaneously evaluate multiple covariates in the same
analysis. The outcome of the regression analysis is
reported as the Relative Diagnostic Odds Ratios (RDOR).
As shown in Table 3, studies that used IS6110 as target of
amplification, and studies that used nested PCR methods
produced RDOR that were significantly higher than those
that used other amplification targets or PCR methods. We
present the SROC curves for these subgroups in figures 3A
and 3B for target and amplification technique,
respectively, to show the trade off between sensitivity and
specificity. Blinding, detection technique and smear status
showed a slightly higher RDOR but they were not statisti-
cally significant in the final regression model. Chemical-
based DNA extraction did not produce a significant
RDOR, indicating that the use of any chemical reagent for
DNA extraction did not substantially affect diagnostic
accuracy. No difference was seen in DOR in those studies
that used phenol-chloroform versus any other DNA
extraction method (data not shown).
Discussion
Principal findings
Diagnostic methods and, therefore, control of tuberculo-
sis would be greatly improved by the standardization and
application of nucleic acid amplification tests. Our meta-
analytical review of 84 in-house PCR-based studies to
detect M. tuberculosis in sputum samples showed a sum-
mary receiver operator characteristic (SROC) of 97%,
indicating an overall high accuracy of these tests. How-
ever, because of significant heterogeneity in sensitivity
and specificity estimates, clinically meaningful estimates
of accuracy could not be derived. Our analysis showed
substantial variability in specificity and sensitivity esti-
mates, and it is clear that in-house PCR tests produce
highly inconsistent estimates of diagnostic accuracy. Het-
erogeneity was clearly evident in the results and could not
been explained fully even after stratified analyses. Varia-
bility in study design, study quality, and differences in
thresholds (cut-points) across studies might account for
some of the observed heterogeneity. Nevertheless, the
meta-regression analysis highlighted some variables that
do appear to yield higher accuracy estimates. The use of
IS6110 as the amplification target, and the use of a nested
PCR protocol appear to enhance accuracy. It is therefore
worth considering the inclusion of these elements in in-
house PCR protocols. Our analyses also suggest that the
methods used for DNA extraction and signal detection
were not critical.
Clinical implications
Because of the observed heterogeneity in sensitivity and
specificity, it is difficult to determine clinically useful esti-
mates of accuracy. On the other hand, our findings have
some relevance for the clinical microbiology laboratory.
Our results suggest that the use of IS6110 target sequence
in the protocol, and the use of nested PCR methods
Table 2: Stratified analysis: effect of study and test characteristics on summary diagnostic odds ratios
Subgroup (Number of studies) Summary DOR (95% CI)
Study design Case-control (24) 134.4 (65.2 – 213.1)
Cross-sectional (60) 171.1 (106.7 – 274.2)
Blinding Single or double blinded (29) 90.2 (46.2 – 176.2)
Unblinded or NR (55) 221.2 (137.7 – 355.2)
DNA extraction method Chemical (55) 153.7 (90.1 – 262.4)
Physical (29) 171.7 (96.2 – 306.6)
Amplification method PCR/multiplex (68) 139.3 (89.2 – 217.7)
Nested PCR (16) 266.6 (140.8 – 504.6)
Target sequence IS6110 (54) 236.1 (152.9 – 364.6)
Other target (30) 77.4 (38.2 – 156.9)
Detection method Probe (49) 130.6 (78.4 – 217.6)
Gel-UV (35) 215.4 (115.1 – 403.2)
Sputum smear status Pos/Both/NR (78) 161.5 (107.5 – 242.6)
Negative (6) 128.6 (33.4 – 495.1)BMC Microbiology 2005, 5:55 http://www.biomedcentral.com/1471-2180/5/55
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appear to significantly increase the diagnostic accuracy of
PCR. In our previous meta-analysis on NAA test for tuber-
culous pleuritis, we found that NAA tests that used IS6110
targets produced DOR estimates 2.5 times higher than
tests that used other target sequences [48]. Lack of blind-
ing has been found to be associated with higher accuracy
in previous meta-analyses [49,53]. Nevertheless we did
not find a significant effect in our meta-regression model.
Our stratified analyses, however, did show that unblinded
studies were associated with higher summary DOR than
blinded studies. Previous empiric research [37] and our
earlier meta-analyses [48,49] suggest that studies that use
a case-control design tend to overestimate diagnostic
accuracy. Surprisingly, study design had little impact on
diagnostic accuracy in our current analyses. It is possible
that laboratory factors (such as target sequence and ampli-
fication technique) had a much stronger impact on accu-
racy than study design features in our analyses.
Limitations of the review
In our review, we found only five studies reporting the
analysis of smear negative specimens. Therefore, we could
not determine the effect of smear status on accuracy of
PCR. Since clinical sputum specimens frequently include
smear-negative samples, the conclusions made in this
meta-analysis may not apply to studies that included a
large number of smear-negative samples. The accuracy
estimates for smear-negative specimens have mostly been
derived from studies on commercial kits, which have
shown high specificity but lower and variable sensitivity
[53]. The US Food and Drug Administration (FDA)
approved the use of specific commercial kits initially only
for smear positive samples, and recently for smear nega-
tive specimens [75]. Our review also excluded more recent
studies that used other protocols for the detection of
amplified DNA, such as real time PCR. We found only
three such studies, and hence they could not be subject to
meta-analyses. In the future, such methods may prove to
enhance NAA test accuracy.
Implications for research
One test characteristic significantly associated with
increased accuracy was the use of IS6110 as a target of
amplification.  IS6110  is present in the M. tuberculosis
genome, usually as multiple copies, which helps to
increase the sensitivity of a PCR test. Potential problem
with using this target is that some strains from certain
parts of the world lack this insertion sequence [76]. A pos-
sible solution may be to use more than one target. How-
ever, we found that multiplex PCR did not contribute to
increase the diagnostic accuracy.
Conclusion
In summary, this meta-analytical review of various proto-
cols for PCR-based diagnosis of pulmonary TB identified
a few factors associated with improved diagnostic accu-
racy, and others that did not make a substantial differ-
ence. Future development of NAA-based tests to detect M.
tuberculosis from sputum specimens should take into con-
sideration these test characteristics as a way to improve
accuracy of in-house NAA tests to diagnose pulmonary TB.
Methods
Identification of studies
We searched the following databases: PUBMED (1985–
2002), EMBASE (1988–2002), Web of Science (1990–
2002), BIOSIS (1993–2002), Cochrane Library (2002;
Issue 2), and LILACS (1990–2002). All searches were up
to date as of August 2002. The PubMed search was
repeated in March 2004, to cover recent literature. The
Journal of Clinical Microbiology, a high-yield journal with
respect to diagnostic studies was separately searched
(1992–2003). The search terms used included "tuberculo-
sis", "mycobacterium tuberculosis", "nucleic acid
Table 3: Meta-regression analysis to determine sources of heterogeneity
Covariate Coefficient P-value Relative diagnostic odds 
ratio (RDOR)
95% confidence interval
Intercept 3.248 0.0052 ---- ----
Threshold (S) - 0.072 0.4522 ---- ----
Case control vs. cross-sectional design - 0.292 0.5219 0.75 (0.30 – 1.85)
Blinded vs. unblinded studies 0.441 0.2795 1.55 (0.69 – 3.48)
Chemical vs. other DNA extraction methods - 0.209 0.5877 0.81 (0.38 – 1.74)
IS6110 vs. other target sequences 1.055 0.0074 2.87 (1.34 – 6.16)
Nested vs. regular amplification protocols 1.196 0.0135 3.31 (1.29 – 8.49)
Probe vs. gel-UV detection methods 0.157 0.7222 1.17 (0.49 – 2.81)
Sputum smear positive/both vs negative 0.242 0.8146 1.27 (0.16 – 9.88)
Intercept: constant term in the model
S: indicator of threshold (logit TPR+logit FPR); TPR: true positive rate; FPR: false positive rate RDOR: relative diagnostic odds ratio (obtained by 
exponentiating the model coefficients)BMC Microbiology 2005, 5:55 http://www.biomedcentral.com/1471-2180/5/55
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amplification techniques", "direct amplification test",
"polymerase chain reaction", "ligase chain reaction",
"molecular diagnostic techniques", "sensitivity and spe-
cificity", "accuracy", or "predictive value". Citations were
searched from multiple databases as well as obtained
from experts in the field and from manufacturers of com-
mercial tests. Reference lists from primary and review arti-
cles were searched. English and Spanish articles were
selected for final full-text review. Conference abstracts
were excluded because they universally contained inade-
quate data to permit evaluation. This criterion had been
used and reported in previous papers [3].
Study eligibility
Our search strategy aimed to include all available studies
on in-house NAA tests for direct detection of M. tuberculo-
sis in sputum specimens. To be included in the meta-anal-
ysis, a study should have: 1) included at least one
comparison of an in-house PCR with an appropriate ref-
erence standard (i.e. culture), for detection of M. tubercu-
losis  complex; 2) provided sufficient information on
sensitivity and specificity; 3) provided enough informa-
tion to judge methodological quality of the study.
The following studies were excluded from the review: 1)
case reports; 2) evaluation of NAA tests on animal speci-
mens; 3) studies on use of PCR assays for typing of strains;
4) studies on use of PCR assays for determining drug
resistance; 5) studies on use of PCR for detection of only
non-tuberculosis mycobacteria and 6) studies using only
commercial NAA kits.
Data extraction
The final analyses included all available studies on in-
house PCR tests for direct detection of M. tuberculosis in
sputum specimens. Two reviewers (LLF and MP) deter-
mined study eligibility independently. After study selec-
tion, data were extracted from each included study using
a standardized data extraction form.
The final set of English and Spanish articles was assessed
by one reviewer (LLF) and a sample of these was assessed
by a second reviewer (MP) to check accuracy in data
extraction. For each study, the following quality criteria
were scored as met or not: 1) independent comparison of
NAA test against reference standard; 2) cross-sectional ver-
sus case-control study design; 3) blinded (single or dou-
ble) interpretation of test and reference standard results.
The test methodology criteria included: 1) species
identification, 2) methodology used for DNA extraction
3) type of PCR performed (nested-seminested vs. regular,
including multiplex), 4) amplification target (IS6110 vs.
any other target) 5) method of detection of the final prod-
uct (ultra-violet (UV) transillumination of an electro-
phoretic gel vs. use of labeled probes for DNA
hybridization), 6) measures taken to avoid contamina-
tion and 7) inclusion of positive and negative controls in
the assay. If no data on the above criteria were reported in
the primary studies, we contacted the authors of the stud-
Effect of Significant Test Characteristics on Summary ROC curves Figure 2
Effect of Significant Test Characteristics on Summary ROC curves: ROC curves for comparison among targets used 
in the in-house PCR assay (A) and different amplification techniques employed in the assays (B).BMC Microbiology 2005, 5:55 http://www.biomedcentral.com/1471-2180/5/55
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ies for such information. For the purposes of analyses,
responses coded as "not reported" were grouped together
with "not met".
Since discrepant analysis (where discordant results
between test and culture results are resolved, post-hoc,
using clinical data) may be a potential source of bias in
NAA test assessments, we preferentially included unre-
solved data where available.
Meta-analysis methods
We used standard methods recommended for meta-anal-
yses of diagnostic test evaluations [6]. Data were analyzed
using Stata (version 8) and Meta-Disc (version 1.1) soft-
ware. Our analyses focused on the following measures of
diagnostic accuracy: sensitivity (true positive rate [TPR]),
specificity (1-false positive rate [FPR]), and diagnostic
odds ratio (DOR). Sensitivity is the proportion positive
test results among those with the target disease. Specificity
is the proportion negative test results among those with-
out the disease. The DOR is a single indicator of test accu-
racy [7] that combines the data from sensitivity and
specificity into a single number. The DOR of a test is the
ratio of the odds of positive test results in the diseased rel-
ative to the odds of positive test results in the non-dis-
eased. The value of a DOR ranges from 0 to infinity, with
higher values indicating better discriminatory test per-
formance (higher accuracy). A DOR of 1.0 indicates that a
test does not discriminate between patients with the dis-
order and those without it. DOR values lower than 1.0
suggest improper test interpretation (a greater proportion
of negative test results in the group with disease). Mathe-
matically, the DOR can be computed using any of the fol-
lowing equations [7]:
DOR = (TP/FN) / (FP/TN)
DOR = [sensitivity/(1 - specificity)] / [(1 - specificity)/spe-
cificity]
DOR = Positive likelihood ratio / Negative likelihood
ratio
Each study in the meta-analysis contributed a pair of
numbers: TPR and FPR. Since these measures are corre-
lated and vary with the thresholds (cut points for deter-
mining test positives) employed in the individual studies,
it is customary to analyze TPR and FPR proportions as
pairs, and to also explore the effect of threshold on study
results [6]. We summarized the joint distribution of sensi-
tivity and specificity using the Summary Receiver Operat-
ing Characteristic (SROC) curve [8]. Unlike a traditional
ROC plot that explores the effect of varying thresholds on
sensitivity and specificity in a single study, each data point
in the SROC space represents a separate study. The SROC
curve is obtained by fitting a symmetric regression curve
to pairs of TPR and FPR. The SROC curve and the area
under it present an overall summary of test performance,
and display the trade off between sensitivity and specifi-
city. A shoulder-like ROC curve suggests that variability in
thresholds employed could, in part, explain variability in
study results. It also suggests a common, homogeneous
underlying DOR that does not change with the diagnostic
threshold. The area under the SROC curve is a global
measure of overall test accuracy. An area under the curve
of 100% indicates perfect discriminatory ability. Hetero-
geneity in meta-analysis refers to a high degree of variabil-
ity in study results [9]. Such heterogeneity could be due to
variability in thresholds (cut-points), disease spectrum,
test methods, and study quality across studies [9]. In the
presence of significant heterogeneity, pooled, summary
estimates from meta-analyses are not meaningful. We
investigated heterogeneity using a meta-regression analy-
sis. The meta-regression analysis was an extension of the
SROC model [8,9]. In this unweighted linear regression
model, studies (and not patients or specimens) were the
units of analysis. The DOR was the outcome (dependent)
variable. The independent variables were the covariates
that might be associated with the variability in the DOR.
Based on our previous meta-analyses [1-3], the following
covariates were specified a priori as potential sources of
variability: study design, blinded interpretation of NAA
test and reference standard, type of PCR test, target
sequence amplified, use of probes to detect amplification
products, and use of phenol-chloroform for DNA extrac-
tion. The results of the meta-regression model are
expressed as relative diagnostic odds ratios (RDOR) [7,9].
An RDOR of 1.0 indicates that a particular covariate (e.g.
blinded study design) does not affect the overall DOR. An
RDOR >1.0 indicates that studies with a particular charac-
teristic (e.g. those that employed a specific target sequence
in the PCR) have a higher DOR than studies without this
characteristic. For a RDOR <1.0, the reverse holds.
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